Deliver Your News to the World

New streamlined assay can improve prenatal detection of alpha-thalassemia

A rapid and accurate test may allow clinical diagnosis and large-scale population screening for couples who may carry a mutation linked to alpha-thalassemia, reports The Journal of Molecular Diagnostics

Philadelphia – WEBWIRE
The superiority and applicability comparison of Sanger sequencing, RDB, and this method for nondeletional α-thalassemia genotyping.
The superiority and applicability comparison of Sanger sequencing, RDB, and this method for nondeletional α-thalassemia genotyping.

In a report in The Journal of Molecular Diagnostics, published by Elsevier, researchers describe a rapid, accurate novel assay for nondeletional alpha-thalassemia genotyping based on one-step nested asymmetric PCR melting curve analysis, which may enhance prenatal diagnosis, newborn screening, and large-scale population screening.

Thalassemia is a group of inherited blood disorders that reduces the ability of blood to circulate oxygen throughout the body. The severity can vary from benign to life threatening; therefore, it is important to identify infants as early as possible who may develop thalassemia-associated symptoms, as well as parents who are carriers. This requires the availability of practical and precise molecular diagnostic tools.

“The nondeletional alpha-thalassemia genotyping assay developed in this study has the advantages of one-step closed-tube operation, high-throughput, speed, and automation, which can meet the methodological needs of a control program for thalassemia in large-scale populations,” explained Wanjun Zhou, PhD, of the Department of Medical Genetics, School of Basic Medical Sciences, Southern Medical University, Guangzhou, China.

Dr. Zhou noted that the strategy of one-step nested asymmetric PCR melting analysis overcomes the bottlenecks of high homology and GC-rich secondary structure that limited previous types of analyses.

Thalassemia affects up to five percent of the world’s population. These disorders are characterized by low levels of hemoglobin, decreased red cell production, and anemia. Patients with thalassemia report fatigue, weakness, shortness of breath, dizziness, or headaches. One subtype, alpha-thalassemia, is caused by one or more mutations in two different genes (HBA1 and HBA2) associated with production of the alpha-globin subunits of hemoglobin. Every individual has two copies of these genes, so up to four genes can be affected; this can determine the severity of symptoms and carrier status. Though the most common type of genetic mutation associated with alpha-thalassemia is deletional (removal of a section of the gene sequence), the assay in this case focuses on point, or nondeletional, mutations.

The researchers tested the ability of the new assay to detect five nondeletional alpha-thalassemia mutations. All five mutations were accurately identified with a concordance rate of 100 percent in a blind analysis of 255 samples with known genotypes, as determined by other analytic methods including gap- PCR, PCR-reverse dot blot (RDB), or Sanger sequencing.

The investigators also tested the capability of the new assay to screen large populations. After testing 1,250 blood samples, the assay showed 100 percent sensitivity and specificity for all of the targeted mutations.

The overall analysis time with the new assay was just under 2.5 hours. This is considerably faster than other molecular genetic testing methods, such as Sanger sequencing, which require 380 minutes, or RDB, which takes 300 minutes.

“These other methods are unsuitable for use in large-scale screening programs because they have limitations such as cumbersome operation, low throughput, subjective interpretation, and possible laboratory contamination caused by post-PCR open-tube operation, commented Dr. Zhou.

“Our results prove that this new assay is accurate, reliable, simple, and rapid and can meet the requirements for clinical diagnosis and mass screening of nondeletional alpha-thalassemia.” Dr. Zhou added that he believes the same strategy may be used in the future for rapid genotyping of other genetic mutations.


The article is “A Nested Asymmetric PCR Melting Curve Assay for One-Step Genotyping of Nondeletional α-Thalassemia Mutations,” by Jiachun Qin, Mingli Xu, Qiang Zhang, Xiaojun Wen, Sheng He, Yong Zhou, Haiping Liu, and Wanjun Zhou ( It will appear in The Journal of Molecular Diagnostics, volume 22, issue 6 (June 2020) published by Elsevier.

About The Journal of Molecular Diagnostics
The Journal of Molecular Diagnostics, the official publication of the Association for Molecular Pathology, co-owned by the American Society for Investigative Pathology, and published by Elsevier, seeks to publish high quality original papers on scientific advances in the translation and validation of molecular discoveries in medicine into the clinical diagnostic setting, and the description and application of technological advances in the field of molecular diagnostic medicine. The editors welcome review articles that contain: novel discoveries or clinicopathologic correlations, including studies in oncology, infectious diseases, inherited diseases, predisposition to disease, or the description of polymorphisms linked to disease states or normal variations; the application of diagnostic methodologies in clinical trials; or the development of new or improved molecular methods for diagnosis or monitoring of disease or disease predisposition.

About Elsevier
Elsevier is a global information analytics business that helps scientists and clinicians to find new answers, reshape human knowledge, and tackle the most urgent human crises. For 140 years, we have partnered with the research world to curate and verify scientific knowledge. Today, we’re committed to bringing that rigor to a new generation of platforms. Elsevier provides digital solutions and tools in the areas of strategic research management, R&D performance, clinical decision support, and professional education; including ScienceDirect, Scopus, SciVal, ClinicalKey and Sherpath. Elsevier publishes over 2,500 digitized journals, including The Lancet and Cell, 39,000 e-book titles and many iconic reference works, including Gray’s Anatomy. Elsevier is part of RELX, a global provider of information-based analytics and decision tools for professional and business customers.

( Press Release Image: )


This news content was configured by WebWire editorial staff. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.